<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03407170</url>
  </required_header>
  <id_info>
    <org_study_id>3475-161</org_study_id>
    <secondary_id>MK-3475-161</secondary_id>
    <nct_id>NCT03407170</nct_id>
  </id_info>
  <brief_title>Immunologic Determinants of Response to Pembrolizumab (MK-3475) in Advanced Melanoma (MK-3475-161/KEYNOTE-161)</brief_title>
  <official_title>An Open-Label, Phase II Study to Determine the Immunologic Correlates of Pembrolizumab-Mediated Tumor Regression in Subjects With Advanced Melanoma (KEYNOTE-161)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, participants with advanced melanoma will be treated with pembrolizumab
      (MK-3475) and their tumors and blood will be analyzed for changes related to pembrolizumab
      therapy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">May 31, 2018</start_date>
  <completion_date type="Anticipated">December 13, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 13, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Fraction of Cytotoxic T-lymphocytes (FCT) for Participants with Response versus Participants with Progression</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>FCT is defined as the fraction of CD8+ T-cells expressing a predefined single-cell RNA gene signature to the total tumor infiltrating CD8+T-cells isolated from tumor biopsies.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Average Specific Cytotoxic T-lymphocyte Frequency Ratio (ASCTFR) for Participants with Response vs Participants with Progression</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>ASCTFR is defined as the arithmetic average of the log^10 ratio of the frequency of individual specific cytotoxic T-Cell Receptor (TCR) clones of on-treatment to pre-treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Baseline of FCT for Participants With Response Versus Participants With Progression</measure>
    <time_frame>Baseline and Month 24</time_frame>
    <description>The fold change from baseline in FCT. FCT is defined as the fraction of CD8+ T-cells expressing a predefined single-cell RNA gene signature to the total tumor infiltrating CD8+T-cells isolated from tumor biopsies.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events (AEs)</measure>
    <time_frame>Up to 27 months</time_frame>
    <description>Number of participants experiencing an AE defined as any untoward medical occurrence in a participant administered a pharmaceutical product temporally associated with the use of study treatment, whether or not considered related to the study treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Discontinuations due to AEs</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Number of participants discontinuing study drug due to an AE.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR) per Immune-related Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>ORR is defined as the percentage of participants in the analysis population who have a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: ≥30% decrease in the sum of diameters of target lesions) per RECIST Version 1.1 as assessed by the investigator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival (PFS) per RECIST Version 1.1</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>PFS is defined as the time from start of treatment to the first documented progressive disease (PD) or death due to any cause, whichever occurs first, per RECIST Version 1.1 as assessed by the investigator..</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>OS is defined as the time from the start of treatment to death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neoepitope Burden</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Neoepitope sequencing will be generated based on single cell RNA sequencing (scRNAseq), whole exome sequencing, and an epitope prediction algorithm to obtain neoepitope burden.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antigenic Determinants of Highly-functional CD8 + T-cell Clones</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>TCRs from CD8+ T-cell clones will be identified by scRNAseq and their killing function will be confirmed by TCR-transduced T-cells recognizing autologous tumor-derived cell lines.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Advanced Melanoma</condition>
  <arm_group>
    <arm_group_label>Pembrolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive pembrolizumab 200 mg by intravenous (IV) infusion every 3 weeks (Q3W) for up to 24 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>pembrolizumab</intervention_name>
    <description>200 mg by IV infusion Q3W for up to 24 months</description>
    <arm_group_label>Pembrolizumab</arm_group_label>
    <other_name>KEYTRUDA®</other_name>
    <other_name>MK-3475</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Has a histologically confirmed diagnosis of unresectable stage III or metastatic
             melanoma not amenable to local therapy

          -  Has testing for a BRAF mutation prior to study entry

          -  Has measurable disease per RECIST 1.1 as assessed by the investigator/radiology

          -  Has resolution of toxic effect(s) of the most recent prior chemotherapy to Grade 1 or
             less (except alopecia). If the participant received major surgery or radiation therapy
             of &gt;30 Gray units, they must have recovered from the toxicity and/or complications
             from the intervention

          -  Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 within
             10 days of study start

          -  Is not pregnant or breastfeeding

          -  Female participants of child-bearing potential must be willing to use effective
             contraception starting with the screening visit through 120 days after the last dose
             of study therapy

        Exclusion Criteria:

          -  Has disease that is suitable for local therapy administered with curative intent

          -  Has a history of interstitial lung disease

          -  Has a positive pregnancy test within 72 hours before the first dose of study therapy

          -  Has received prior therapy with an anti-Programmed Cell Death Protein 1 (PD-1),
             anti-Programmed Cell Death-Ligand 1 (PD-L1), anti-Programmed Cell Death-Ligand 2
             (PD-L2) agent or with an agent directed to another stimulatory or co-inhibitory T-cell
             receptor (eg, CTLA-4, OX-40, CD137)

          -  Has received prior systemic anti-cancer therapy including investigational agents
             within 4 weeks prior to study start

          -  Has received prior radiotherapy within 2 weeks of start of study therapy

          -  Has received a live vaccine within 30 days prior to the first dose of study therapy

          -  Has received transfusion of blood products (including platelets or red blood cells) or
             administration of colony stimulating factors (including granulocyte colony stimulating
             factor [G-CSF], granulocyte macrophage colony stimulating factor [GMCSF] or
             recombinant erythropoietin) within 4 weeks prior to study start

          -  Is currently participating in or has participated in a study of an investigational
             agent or has used an investigational device within 4 weeks prior to the first dose of
             study therapy

          -  Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy
             or any other form of immunosuppressive therapy within 7 days prior the first dose of
             study therapy

          -  Has a known additional malignancy that is progressing or has required active treatment
             within the past 3 years with the exception of basal cell and squamous cell carcinoma
             of the skin, transitional cell carcinoma of urothelial cancer, or carcinoma in situ
             (eg, breast carcinoma, cervical cancer in situ) that have undergone potentially
             curative therapy

          -  Has known active CNS metastases and/or carcinomatous meningitis

          -  Has severe hypersensitivity (≥Grade 3) to pembrolizumab and/or any of its excipients

          -  Has an active autoimmune disease that has required systemic treatment in past 2 years

          -  Has a history of (non-infectious) pneumonitis that required steroids or has current
             pneumonitis

          -  Has an active infection requiring systemic therapy

          -  Has a known history of human immunodeficiency virus (HIV) infection

          -  Has a known history of Hepatitis B (defined as Hepatitis B surface antigen [HBsAg]
             reactive) or known active Hepatitis C virus (defined as HCV RNA [qualitative] is
             detected) infection

          -  Has a history or current evidence of any condition, therapy, or laboratory abnormality
             that might confound the results of the study, interfere with the participant's
             participation for the full duration of the study, or is not in the best interest of
             the participant to participate, in the opinion of the treating investigator

          -  Has known psychiatric or substance abuse disorders that would interfere with
             cooperating with the requirements of the study

          -  Is pregnant or breastfeeding or expecting to conceive or father children starting with
             the screening visit through 120 days after the last dose of study therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Toll Free Number</last_name>
    <phone>1-888-577-8839</phone>
    <email>Trialsites@merck.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Massachusetts General Hospital ( Site 0102)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>617-724-4800</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute ( Site 0101)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>617-582-9992</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 18, 2018</study_first_submitted>
  <study_first_submitted_qc>January 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 23, 2018</study_first_posted>
  <last_update_submitted>May 9, 2018</last_update_submitted>
  <last_update_submitted_qc>May 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Programmed Cell Death-1 (PD-1)</keyword>
  <keyword>PD1</keyword>
  <keyword>Programmed Cell Death-Ligand 1 (PD-L1)</keyword>
  <keyword>Programmed Cell Death-Ligand 2 (PD-L2)</keyword>
  <keyword>PDL1</keyword>
  <keyword>PDL2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

